Literature DB >> 23183136

TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in individuals with APOE ε3/ε3.

Ge Li1, Lynn M Bekris, Lesley Leong, Ellen J Steinbart, Jane B Shofer, Paul K Crane, Eric B Larson, Elaine R Peskind, Thomas D Bird, Chang-En Yu.   

Abstract

BACKGROUND: This study investigates the association between TOMM40 poly-T length, age at onset, and neuropathology in individuals with Alzheimer's disease (AD) with the apolipoprotein E (APOE) ε3/ε3 allele.
METHODS: Thirty-two presenilin 1 (PSEN1) mutation carriers with AD, 27 presenilin 2 (PSEN2) mutation carriers with AD, 59 participants with late-onset AD (LOAD), and 168 autopsied subjects from a community-based cohort were genotyped for TOMM40 intron 6 poly-T (rs10524523) length using short tandem repeat assays.
RESULTS: Among AD individuals with PSEN2 mutations, the presence of a long poly-T was associated with an earlier age at onset, whereas there were no such associations for subjects with PSEN1 mutations or LOAD. In community-based participants, the presence of a long poly-T was associated with increased neuritic tangles and a greater likelihood of pathologically diagnosed AD.
CONCLUSION: TOMM40 intron 6 poly-T length may explain some of the variation in age at onset in PSEN2 familial AD and may be associated with AD neuropathology in persons with APOE ε3/ε3.
Copyright © 2013 The Alzheimer's Association. All rights reserved.

Entities:  

Keywords:  APOE; Age at onset; Alzheimer’s disease; Genetic; Neuropathology; PSEN1 mutation; PSEN2 mutation; TOMM40

Mesh:

Substances:

Year:  2012        PMID: 23183136      PMCID: PMC3606272          DOI: 10.1016/j.jalz.2012.06.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  39 in total

Review 1.  Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors:  E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

2.  Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.

Authors:  Carlos Cruchaga; Petra Nowotny; John S K Kauwe; Perry G Ridge; Kevin Mayo; Sarah Bertelsen; Anthony Hinrichs; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  Arch Neurol       Date:  2011-08

3.  TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.

Authors:  Su Hee Chu; Kathryn Roeder; Robert E Ferrell; Bernie Devlin; Mary Ann A DeMichele-Sweet; M Ilyas Kamboh; Oscar L Lopez; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2011-08-05       Impact factor: 4.673

4.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Authors:  A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

5.  Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

Authors:  S Kim; S Swaminathan; L Shen; S L Risacher; K Nho; T Foroud; L M Shaw; J Q Trojanowski; S G Potkin; M J Huentelman; D W Craig; B M DeChairo; P S Aisen; R C Petersen; M W Weiner; A J Saykin
Journal:  Neurology       Date:  2010-12-01       Impact factor: 9.910

6.  Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Authors:  Jonathan M Schott
Journal:  Neurobiol Aging       Date:  2011-04-03       Impact factor: 4.673

7.  The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.

Authors:  Sterling C Johnson; Asenath La Rue; Bruce P Hermann; Guofan Xu; Rebecca L Koscik; Erin M Jonaitis; Barbara B Bendlin; Kirk J Hogan; Allen D Roses; Ann M Saunders; Michael W Lutz; Sanjay Asthana; Robert C Green; Mark A Sager
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

8.  Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Authors:  Mi-Ryung Han; Gerard D Schellenberg; Li-San Wang
Journal:  BMC Neurol       Date:  2010-10-08       Impact factor: 2.474

9.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort.

Authors:  Li Shen; Sungeun Kim; Shannon L Risacher; Kwangsik Nho; Shanker Swaminathan; John D West; Tatiana Foroud; Nathan Pankratz; Jason H Moore; Chantel D Sloan; Matthew J Huentelman; David W Craig; Bryan M Dechairo; Steven G Potkin; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neuroimage       Date:  2010-01-25       Impact factor: 6.556

10.  Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE.

Authors:  Lynn M Bekris; Franziska Lutz; Chang-En Yu
Journal:  J Hum Genet       Date:  2011-11-17       Impact factor: 3.172

View more
  22 in total

Review 1.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

2.  The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes.

Authors:  Lior Greenbaum; Ramit Ravona Springer; Michael W Lutz; Anthony Heymann; Irit Lubitz; Itzik Cooper; Efrat Kravitz; Mary Sano; Allen D Roses; Jeremy M Silverman; Ann M Saunders; Michal Schnaider Beeri
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-13       Impact factor: 4.600

3.  The association between TOMM40 gene polymorphism and spontaneous brain activity in amnestic mild cognitive impairment.

Authors:  Xiaoyan Liu; Feng Bai; Chunxian Yue; Yongmei Shi; Hui Yu; Benyan Luo; Zhijun Zhang
Journal:  J Neurol       Date:  2014-05-18       Impact factor: 4.849

4.  Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline.

Authors:  Lei Yu; Michael W Lutz; Jose M Farfel; Robert S Wilson; Daniel K Burns; Ann M Saunders; Philip L De Jager; Lisa L Barnes; Julie A Schneider; David A Bennett
Journal:  Alzheimers Dement       Date:  2017-06-15       Impact factor: 21.566

5.  Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study.

Authors:  Michael W Lutz; Ramon Casanova; Santiago Saldana; Maragatha Kuchibhatla; Brenda L Plassman; Kathleen M Hayden
Journal:  Neurobiol Aging       Date:  2019-03-06       Impact factor: 4.673

6.  The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging.

Authors:  William K Gottschalk; Michael W Lutz; Yu Ting He; Ann M Saunders; Daniel K Burns; Allen D Roses; Ornit Chiba-Falek
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-11

Review 7.  The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.

Authors:  Ornit Chiba-Falek; William K Gottschalk; Michael W Lutz
Journal:  Alzheimers Dement       Date:  2018-03-07       Impact factor: 21.566

8.  TOMM40'523 variant and cognitive decline in older persons with APOE ε3/3 genotype.

Authors:  Lei Yu; Michael W Lutz; Robert S Wilson; Daniel K Burns; Allen D Roses; Ann M Saunders; Chris Gaiteri; Philip L De Jager; Lisa L Barnes; David A Bennett
Journal:  Neurology       Date:  2017-01-20       Impact factor: 9.910

9.  Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.

Authors:  Cynthia M Stonnington; Brian Harel; Dona E C Locke; Joseph G Hentz; Nan Zhang; Paul Maruff; Richard J Caselli
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Oct-Dec       Impact factor: 2.703

Review 10.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.